You are here: Industry Insights > Navigator

News List

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA drugs
May 31, 2021
AMGN today announced its partner AZN submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.
Tezepelumab significantly reduces exacerbations of severe asthma europeanpharmaceuticalreview
March 02, 2021
In a Phase III trial, tezepelumab was shown to meaningfully reduce annualised asthma exacerbation rates in a range of patients with severe, uncontrolled asthma.
Tezepelumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
January 08, 2021
Amgen and AstraZeneca announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo.
Tezepelumab Trial Meets Primary Endpoint americanpharmaceuticalreview
November 20, 2020
Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe ...
Bayer Receives FDA Approval of myBETAapp and BETACONNECT Navigator biospectrumasia
June 01, 2017
With this software in relapsing-remitting multiple sclerosis, patients can use Bluetooth technology to connect their current autoinjector to the new myBETAapp on their mobile device or computer.